Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Advita Lifescience GmbH currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner, which indicates a concentrated prosecution focus. The portfolio is also limited to 1 distinct art unit, suggesting that the company's current legal challenges are confined to a specific technical group within the patent office.
The busiest examiner for these matters is ESPINOSA, CLAUDIA EDILMA, who is responsible for 1 busiest examiner pending action. Having 1 distinct examiner means that the prosecution strategy does not need to account for varying examiner behaviors across different applications. Furthermore, the 1 distinct art unit involved ensures that the procedural standards remain consistent across the current filing.
ESPINOSA, CLAUDIA EDILMA holds 1 busiest examiner pending action, which represents the entirety of the company's current pending workload. This concentration in the Biotechnology & Pharmaceuticals area allows for a focused approach to resolving the 1 pending office action. Practitioners should note that the involvement of the assigned art unit may simplify the administrative aspects of the prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17595025 | VASOACTIVE INTESTINAL PEPTIDE (VIP) FOR USE IN THE TREATMENT OF DRUG-INDUCED PNEUMONITIS | ESPINOSA, CLAUDIA EDILMA | 79d |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17595025 | VASOACTIVE INTESTINAL PEPTIDE (VIP) FOR USE IN THE TREATMENT OF DRUG-INDUCED PNEUMONITIS | ESPINOSA, CLAUDIA EDILMA | 1654 | §103 | Final Rejection | 79d | Pending | Nov 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial